Baird Medical Highlights Strategic Engagement at 2026 J.P. Morgan Healthcare Conference

Baird Medical (NASDAQ: BDMD) participated at the 44th Annual J.P.

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) participated at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 20, 2026, where leadership met with institutional investors and healthcare veterans.

Discussions emphasized Baird Medical's 2026 strategic priorities: accelerating its U.S. commercial footprint and expanding adoption of its minimally invasive Microwave Ablation (MWA) thyroid technologies. The company stated these engagements reinforced market interest in its differentiated MWA platform and confirmed alignment with investors on clinical and growth objectives. Management said it will focus on executing its operational roadmap to enhance shareholder value and broaden patient access to its technologies.

Argus Jan 20 session

-0.87% close to close Open Argus

Details

News Market Reaction – BDMD

On Jan 20, the day this news came out, BDMD closed 0.87% below the previous close.

Data tracked by StockTitan Argus for the Jan 20 session.

Market Context

This announcement highlights Baird Medical’s use of the J.P. Morgan Healthcare Conference to deepen ...

Analysis

This announcement highlights Baird Medical’s use of the J.P. Morgan Healthcare Conference to deepen engagement with institutional investors and emphasize its U.S. commercial build-out for its MWA thyroid ablation platform. Recent history shows a series of geographic expansions, manufacturing moves, and leadership additions. Alongside these, the latest 424B3 filing registering 11,500,000 warrant shares and 34,415,562 resale shares, and disclosed China/HFCAA-related risks, remain important backdrop factors to monitor.

Key Figures

Warrant shares registered: 11,500,000 shares Resale shares registered: 34,415,562 shares Resale ownership share: 70.9% +5 more

Warrant shares registered

11,500,000 shares

Ordinary shares issuable upon exercise of public warrants at US$11.50

Resale shares registered

34,415,562 shares

Ordinary shares registered for resale by existing shareholders

Resale ownership share

70.9%

Assumed percentage of outstanding shares represented by resale registration

Warrant exercise price

US$11.50

Exercise price for public warrants registered in 424B3

Reference share price

US$1.63

Nasdaq share price cited as of December 4, 2025 in filing

Price change

-8%

BDMD 24h move prior to this conference news

Trading volume

184,866 shares

Today vs 20-day average volume of 75,639 shares (2.44x)

Market cap

$42,234,784

Equity value prior to this announcement

Historical Context

5 past events · Latest: Jan 07

5 events

1. Jan 07

   Regulatory approvals

   24h Move

   +3.9%

   Product registrations in Pakistan and Vietnam supporting global MWA expansion.

2. Dec 17

   Manufacturing expansion

   24h Move

   +2.2%

   Establishment of U.S. manufacturing base with MPS Medical for global supply.

3. Dec 08

   Clinical training

   24h Move

   -4.9%

   Advanced MWA training for Arizona surgeon with three live procedures.

4. Dec 03

   Leadership change

   24h Move

   +11.1%

   Appointment of experienced U.S. CEO to drive commercial expansion.

5. Nov 03

   Market entry

   24h Move

   -9.2%

   Entry into Egyptian market with first successful bone tumor ablation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

microwave ablation, warrants, public warrants, prospectus, +2 more

6 terms

microwave ablation medical

"a market leader in minimally invasive Microwave Ablation (MWA) technology"

Microwave ablation is a medical procedure that uses focused microwave energy to heat and destroy abnormal tissue, such as tumors, through a needle-like probe inserted into the body; think of it as using a tiny, targeted microwave oven to cook away problem cells without large incisions. It matters to investors because it represents a growing category of minimally invasive treatments that can reduce hospital stays, create demand for specialized devices and disposables, and influence reimbursement and adoption trends in healthcare markets.

warrants financial

"shares issuable upon exercise of public warrants at US$11.50 per share"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

public warrants financial

"ordinary shares issuable upon exercise of public warrants at US$11.50"

Public warrants are tradable securities that give the holder the right to buy a company’s stock at a fixed price before a set expiration date. Like a coupon that lets you purchase shares later at a preset price, they matter to investors because using them can bring new cash into the company but also increase the total number of shares outstanding, which can dilute existing ownership and influence the stock’s price and potential gains.

prospectus regulatory

"has filed a prospectus to register up to 11,500,000 ordinary shares"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

ipo financial

"supporting NeuroPace through a $117M IPO"

An initial public offering (IPO) is the process by which a private company sells its shares to the public for the first time, making its ownership available on the stock market. This allows the company to raise money from a wide range of investors to fund growth or other goals. For investors, an IPO offers a chance to buy into a company early in its public journey, potentially benefiting if the company grows in value.

View in glossary

hfCAA regulatory

"warns that HFCAA-related auditor inspection issues could eventually lead to"

The HFCAA is a U.S. law that requires companies listed on U.S. stock exchanges to allow their auditors to be inspected by U.S. regulators; if a company’s auditors can’t be reviewed for several years, the company risks being removed from U.S. markets. For investors, it matters because the law increases transparency and audit oversight—think of it as a safety inspection for a car—while also creating a clear regulatory trigger that can affect a stock’s availability and price if compliance can’t be shown.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Jan. 20, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its successful participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.

During the conference week, the Company's leadership team, including U.S. CEO Mark Saxton, held a series of meetings with institutional investors and healthcare industry veterans. These discussions focused on Baird Medical's 2026 strategic priorities, specifically the acceleration of its U.S. commercial footprint and the continued adoption of its thyroid ablation technologies.

"Our interactions in San Francisco reaffirmed the market's interest in our differentiated MWA platform," said Mark Saxton, U.S. CEO of Baird Medical. "We appreciated the opportunity to align with the investment community on our vision for the year ahead, which remains centered on driving clinical excellence and sustainable growth."

Following these productive engagements, Baird Medical remains focused on executing its operational roadmap to enhance shareholder value and expand patient access to its minimally invasive solutions.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-highlights-strategic-engagement-at-2026-jp-morgan-healthcare-conference-302664681.html

SOURCE BDMD

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Baird Medical (NASDAQ: BDMD) highlight at the January 20, 2026 J.P. Morgan Healthcare Conference?

Baird Medical highlighted plans to accelerate its U.S. commercial footprint and drive adoption of its thyroid MWA technology.

Who from Baird Medical met with investors at the 2026 J.P. Morgan Healthcare Conference?

The company's leadership team, including U.S. CEO Mark Saxton, held meetings with institutional investors and healthcare industry veterans.

How did Baird Medical describe investor interest after the J.P. Morgan conference?

Management said the meetings reaffirmed market interest in its differentiated MWA platform and aligned investors with its 2026 priorities.

Will Baird Medical's conference meetings affect its 2026 strategy for BDMD shareholders?

Management indicated the engagements support execution of its operational roadmap aimed at enhancing shareholder value and expanding patient access.

What commercial focus did Baird Medical emphasize for 2026 on the BDMD roadmap?

The company emphasized accelerating U.S. commercial expansion and continuing clinical adoption of its minimally invasive thyroid ablation technologies.